BCAX (Bicara Therapeutics) Net Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Bicara Therapeutics's Net Income for the three months ended in Sep. 2024 was $-17.48 Mil. Bicara Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Bicara Therapeutics's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Bicara Therapeutics's Net Margin % or its related term are showing as below:

BCAX's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -132.42
* Ranked among companies with meaningful Net Margin % only.

Bicara Therapeutics Net Margin % Historical Data

The historical data trend for Bicara Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Net Margin % Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Net Margin %

Bicara Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Net Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's Net Margin %

For the Biotechnology subindustry, Bicara Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Net Margin % falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Bicara Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-51.985	/	0
	=	%

Bicara Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin	=	Net Income (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-17.481	/	0
	=	%

Bicara Therapeutics (NAS:BCAX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Bicara Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.